Altimmune, Inc. (ALT) vs ProKidney Corp. (PROK)

A side-by-side comparison of Altimmune, Inc. and ProKidney Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALT vs PROK

growth of $100 · dividends reinvested · last 5y
ALT -83.2% (-30.0%/yr)PROK -84.4% (-31.0%/yr)ALT compounded faster over this window
050100Start $10020222023202420252026$17$16
ALT PROK

ALT vs PROK: by the numbers

  • •PROK is the larger company ($536M vs $519M market cap).
  • •Both run net losses; PROK's is the smaller (-10599.76% vs -296000.00% net margin).

Metrics side by side

Valuation

MetricALTPROK
P/S ratio16749.86655.65
P/B ratio1.09N/A

Profitability

MetricALTPROK
Gross margin100.00%100.00%
Operating margin-230460.98%-18477.83%
Net margin-296000.00%-10599.76%
ROE-19.35%N/A
ROIC-19.47%-78.31%

Growth (annualized)

MetricALTPROK
Revenue CAGR (5Y)-65.38%N/A
Total return CAGR (5Y)-25.30%-30.65%

Frequently asked

How have ALT and PROK total returns compared?
Over the past 5 years, ALT delivered -25.30% and PROK delivered -30.65% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.